On Monday, news filtered through that the vaccine being developed by Pfizer and BioNTech is 90% effective - with zero safety concerns raised during its testing phase during which it was used on 43,500 people.
The sensation of relief that swept the country on Monday was understandable.
During the afternoon, news filtered through that a vaccine being developed by Pfizer and BioNTech has been confirmed to be 90% effective – with zero safety concerns raised from its testing phase during which it was used on 43,500 people.
This is as close as we’ve been to the prospect of immunisation since the pandemic took hold.
Chief Medical Officer Chris Whitty called the news “very encouraging”, whilst Deputy CMO Jonathan Van-Tam even suggested there could be a vaccine by Christmas – with a “much better horizon by spring.”
Preliminary news that the Pfizer/BioNTech vaccine is effective demonstrates the power of science against COVID. We must see the final safety and efficacy data, but it is very encouraging.
It is essential we continue to suppress COVID, but it is a reason for optimism for 2021.
Prime Minister Boris Johnson – who himself must have been buoyed by the very real prospect of a magic jab after a torrid few months leading the nation – urged caution.
He warned it was still “very, very early days”, and that “the biggest mistake we could make now would be to slacken our resolve at a critical moment.”
ADVERTISEMENT
Van Tam also admitted that setbacks during the distribution of a vaccine could easily happen, and attempted to clarify the situation with a football analogy.
“[We] haven’t won the cup yet, but what it does is it tells you that the goalkeeper can be beaten,” he said.
Here’s what we know about the new vaccine so far…
ADVERTISEMENT
Unsplash
How does the vaccine work?
The Pfizer and BioNTech vaccine works by teaching the immune system to combat coronavirus.
Two doses are required – three weeks apart – for maximum effect.
The vaccine involves injecting people with a tiny bit of the virus which the immune system immediately recognises as a threat and learns how to defeat; thereby offering future protection.
According to developers, 9 out of 10 people who receive the vaccine will not get COVID symptoms.
Who will get it first?
The most vulnerable people in the UK will have first dibs on any vaccine.
ADVERTISEMENT
This means it’s likely to be distributed to care homes and hospitals – locations the virus has hit hardest.
Frontline workers may also be prioritised for doses.
The expectation is that the older you are, the sooner you will be eligible for the coronavirus vaccine.
Younger people are likely to be lower down the list unless they have a condition that categorises them as vulnerable.
But the answer as to whether the vaccine will work in the long-term is a case of wait and see.
There are apparently some logistical challenges to storing the vaccine, too – with doses having to be kept at -80 degrees (facilities a humble GP surgery or pharmacy would not have).
The virus may also mutate later down the line, which would mean the vaccine would have to be tweaked in order to remain effective.
When will lockdowns stop?
Once the vaccine is ready, the challenge is getting it to the people who need it most.
This will take time, and until then, social restrictions remain of crucial importance in the fight against COVID-19.
ADVERTISEMENT
Is the UK getting the Pfizer and BioNTech vaccine?
Yes.
Britain has ordered 30 million doses.
What about other vaccines?
There are around a dozen vaccines in the final stages of development – with news expected on these in the coming weeks and months.
However, the Pfizer vaccine appears to be the lead candidate.
The BBC’s Health and science correspondent, James Gallagher, stated: “We are still waiting for the full data, but these results are even better than people were hoping for.
“A good flu vaccine protects around half of people, so 90% at the first attempt is a triumph.”
News
NHS urgently needs 500,000 men to take part in ‘major’ cancer research programme
Emily Sergeant
Half a million men are needed to take part in a ‘major’ cancer research programme.
From this week, the NHS has announced that it will begin contacting 500,000 men to invite them to join a major research programme that will work to improve the vital early detection and treatment of prostate cancer.
Men who have had or are living with prostate cancer will receive letters and text messages explaining how they can register to take part.
It’s hoped that this will become one of the world’s largest prostate cancer studies.
Formally named ‘Prostate Progress’, the study is designed to speed up the development of better tests, treatments, and care – with the NHS aiming to recruit as many participants as possible to improve how prostate cancer is diagnosed and treated, as well as understanding the side effects of treatment and the impact they have on quality of life.
The NHS urgently needs 500,000 men to take part in a ‘major’ cancer research programme / Credit: rawpixel
Prostate cancer is now the most common cancer in the UK, with around 60,000 new cases diagnosed every year and over 12,000 deaths annually.
Men who join ‘Prostate Progress’ will be asked to complete questionnaires about their experiences of living with the disease every few months.
Verified researchers will then be able compare men’s experiences of living with prostate cancer against their NHS records – including their symptoms and quality of life.
The NHS says it is ‘particularly keen’ to hear from black men for the programme, as they are at approximately twice the risk of developing prostate cancer – with around one in four black men in the UK expected to be diagnosed during their lifetime.
“Better representation will help researchers understand and address differences in diagnosis, treatment and outcomes,” the NHS said in a statement.
“Prostate cancer is now the most common cancer in the UK,” explained Health Minister, James Frith. “Every piece of data we gather brings us closer to the tests and treatments that future patients will depend on to live well for longer.
“Prostate Progress has the potential to become a hugely important resource, but only if men come forward and share their experiences, so I encourage anyone who receives an invitation to sign up.
“This is the kind of innovation the government’s National Cancer Plan is designed to support, making the NHS a world-leading destination for cancer research and ensuring patients across the country can help shape the treatments of tomorrow.”
Featured Image – Vitaly Gariev (via Unsplash)
News
Police charge and name man after broad daylight stabbing of 19-year-old in Northern Quarter
Emily Sergeant
A man has been charged and publicly named after the stabbing of a teenager in the Northern Quarter last week.
Bandar Alzahar has been charged with attempted murder and possession of a bladed article in a public place, and has been remanded in custody ahead of a scheduled appearance at Manchester & Salford Magistrates Court today (Monday 3 August 2026).
The charges come after a 19-year-old man was stabbed in the Northern Quarter, in Manchester city centre, last Friday (31 July).
The shocking incident took place in broad daylight at around 12:50pm on Church Street.
After police attended the scene, they ‘quickly located’ a suspect – initially described as just being a man in his early 20s – at Manchester Airport within three hours of the incident occurring, and he was subsequently arrested on suspicion of Section 18 assault.
The victim sadly remains in hospital in a stable condition but with life-threatening injuries, police have confirmed.
Greater Manchester Police (GMP) are still appealing to the public for information. In a public plea, police wrote: “We are still asking for information from anyone that may have witnessed the incident on Church Street to get in touch with us.
“This includes any CCTV, mobile phone or Dashcam footage that may assist our enquiries.”
Any information can be submitted to GMP by calling 101, quoting log 1580 of 31/07/2026. Alternatively, you can contact independent charity Crimestoppers on 0800 555 111.